The role of prolactin/vasoinhibins in cardiovascular diseases  

作　　者：Hui Zhao Sugang Gong Yongcong Shi Cijun Luo Hongling Qiu Jing He Yuanyuan Sun Yuxia Huang Shang Wang Yuqing Miao Wenhui Wu 

机构地区：[1]School of Materials and Chemistry&Institute of Bismuth and Rhenium,University of Shanghai for Science and Technology,Shanghai,China [2]Department of Cardio-Pulmonary Circulation,School of Medicine,Shanghai Pulmonary Hospital,Tongji University,Shanghai,China [3]Respiratory Medicine,Dongchuan District People's Hospital,Kunming,China

出　　处：《Animal Models and Experimental Medicine》2023年第2期81-91,共11页动物模型与实验医学（英文）

基　　金：National Natural Science Foundation of China,Grant/Award Number:81700045,81870042 and 81900050;Natural Science Foundation of Shanghai,Grant/Award Number:22ZR1452400;Shanghai Municipal Commission of Health,Grant/Award Number:20204Y0384;Shanghai Pulmonary Hospital,Grant/Award Number:fk18003 and fkyq1605。

摘　　要：Prolactin(PRL)is a polypeptide hormone that is mainly synthesized and secreted by the lactotroph cells of the pituitary.There are two main isoforms of PRL:23-kDa PRL(named full-l ength PRL)and vasoinhibins(including 5.6–18 kDa fragments).Both act as circulating hormones and cytokines to stimulate or inhibit vascular formation at different stages and neovascularization,including endothelial cell proliferation and migration,protease production,and apoptosis.However,their effects on vascular function and cardiovascular diseases are different or even contrary.In addition to the structure,secretion regulation,and signal transduction of PRL/vasoinhibins,this review focuses on the pathological mechanism and clinical significance of PRL/vasoinhibins in cardiovascular diseases.

关 键 词：cardiovascular diseases endothelial cells prolactin vasoinhibins 

分 类 号：R54[医药卫生—心血管疾病]